Unicycive Therapeutics, Inc.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $675.0K
- Net income
- -$26.6M
- Total assets
- $49.1M
- Market cap
- $184.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $29.5M
- Operating income
- -$29.5M
- Net income
- -$26.6M
- EPS (basic)
- $-1.67
- EPS (diluted)
- $-1.67
Balance sheet
- Total assets
- $49.1M
- Current assets
- $49.0M
- Total liabilities
- $18.9M
- Current liabilities
- $18.9M
- Shareholders’ equity
- $30.2M
Cash flow
- Operating cash flow
- -$31.3M
- Investing cash flow
- -$12.1M
- Financing cash flow
- $46.5M
- Net cash flow
- $3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $184.8M
- EPS (diluted)
- $-1.67
- Shares outstanding
- 27.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 13, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.6M in FY2023.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Unicycive Therapeutics, Inc..
Write a review
News about Unicycive Therapeutics, Inc.
News & sentiment via Polygon.io
